Biogen (BIIB) Tops Q4 EPS by 25c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $212.50 -3.77%
EPS Growth %: -57.8%
Financial Fact:
Other: 98.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -57.8%
Financial Fact:
Other: 98.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $6.99, $0.25 better than the analyst estimate of $6.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.39 billion.
GUIDANCE:
Biogen sees FY2019 EPS of $28.00-$29.00, versus the consensus of $28.02. Biogen sees FY2019 revenue of $13.6-13.8 billion, versus the consensus of $13.63 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
